Podcast: Play in new window | Download (Duration: 1:15:57 — 57.5MB) | Embed
Subscribe: Apple Podcasts | Spotify | Amazon Music | Android | Pandora | iHeartRadio | Blubrry | Podcast Index | Email | TuneIn | RSS | More
E-vaccine, catabodies, healthy ageing,and age-associated diseases discussed with Stephanie and Sudhir founders of Covalent Bioscience.
Covalent Bioscience’s Mission
“We want to develop and successfully create affordable, better antibodies and vaccines for a range of unmet medical needs.
We hope to attain this ambition by applying the Catabody and E-Vaccine platform technologies, which promise to generate multiple products for treating and preventing life-threatening diseases.
Our lead catabodies focus on healthy aging and age-associated diseases. Our lead E-Vaccine holds promise for effective prophylaxis and therapy of HIV infection. Our technology platforms have disruptive potential as innovative solutions to significant public health challenges world-wide in both developed and developing countries.”
About the Team
“Our inventions and discoveries over 30+ years of academic research have brought the Catalytic Immunotherapy/E-vaccine technologies to the brink of medical intervention.
We are now focused on marketable products and services. We are capitalizing Covalent Bioscience to develop: (a) Our lead catabodies for treating amyloid diseases of the heart, musculoskeletal system and brain (catabodies to transthyretin, amyloid beta and tau) and our lead E-vaccine for prophylaxis and therapy of HIV infection, and (b) Our contract services for on-demand production of catabodies and E-vaccines directed to any pre-specified target protein.
- Paul and Massey have worked on catalytic antibodies (Catabodies) and electrophilic vaccines (E-vaccines) since 1980s.
- Massey was COO of IGEN (Nasdaq: IGEN), raised over USD 100 MM in private equity/licensing deals, and participated in the USD 2BB buyout of his company.Paul’s discovery of harmful catabodies in autoimmune disease was central to the USD 21 MM buyout of his early discovery patents by Abgenix in 2001. More important, the discovery patents progressed to our current on-demand technology platform for therapeutic catabodies and preventive/therapeutic E-vaccines.
- Planque participated in defining major mechanistic and evolutionary concepts behind our technologies as a senior member of Paul’s group, which was awarded over USD 30MM research funds at the Univ of Texas and the Univ of Nebraska (NIH, non-profit foundations, private sector).
- Abzyme Research Foundation (ARF) has made a non-profit Mission-Related Investment in our candidate HIV vaccine. ARF managed the non-profit EndHIVCampaign, and it has developed unique insights to the societal/financial aspects of US investments in HIV vaccine/cure funding. Both Covalent and ARF are fully sensitive to the world-wide need for prophylactic vaccination if HIV is to be eradicated.”
links
About this podcast
The Learning with Lowell; Science, deep tech, biotech, startup, and news podcast has new episodes every Tuesday. It is hosted by Lowell Thompson who started the podcast after suffering through e genetic illness that almost almost saw him die on a number of occasions, but now is managed and doesn’t cause too many problems. Lowell’s goal is to educate people on the different paths you can take to get into a science, deep tech, biotech, or startup related venture as a founder or member of the team. Additionally, Lowell wants to show you who these founders and experts are like as they answer questions about their work, passions, and interest.
Subscribe today: http://www.learningwithlowell.com/subscribe-here/
Subscribe to our Youtube: https://www.youtube.com/channel/UChstfGtxlrNK6lfmvk4cBpA?view_as=subscriber
Join the newsletter:http://www.learningwithlowell.com/5-point-monday-email-subscription/
Like and share on
Twitter: https://twitter.com/lowellwashere
Facebook: https://www.facebook.com/LearningWithLowell/
and Linkedin: https://www.linkedin.com/in/lowell-thompson-2227b074/